Contacts

 MedinCell announces its participation in the Jefferies London Healthcare Conference 2022, 15-17 November in London 

November 9, 2022

 The conference will provide an opportunity to present to investors the recent and upcoming news from MedinCell, including : 

  • Refiling for approval of UzedyTM by its partner Teva, which has confirmed that it plans to commercialize it in the U.S. in the first half of 2023 
  • Launch by Teva of Phase 3 activities in the U.S. for a second treatment, mdc-TJK 
  • Launch by MedinCell’s partner, Arthitris Innovation Corporation (AIC), of Phase 3 activities for F14/mdc-CWM, a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement 
  • Advances in the experimental product portfolio at the formulation and pre-clinical stages 

Members of the MedinCell management will meet investors during individual meetings. 

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.